Emergent BioSolutions (EBS) Interest Expenses (2011 - 2026)

Emergent BioSolutions' Interest Expenses history runs 16 years deep, the most recent figure standing at $11.0 million for Q1 2026.

• In Q1 2026, Interest Expenses fell 25.17% year-over-year to $11.0 million; the TTM figure through Mar 2026 stood at $55.6 million (down 9.45% YoY), while the FY2025 annual figure was $59.3 million, down 16.48% from the prior year.
• Interest Expenses was $11.0 million for Q1 2026 at Emergent BioSolutions, down from $14.7 million in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $28.6 million in Q2 2023 to a low of $7.8 million in Q2 2022.
• Historically, Interest Expenses has averaged $15.7 million across 5 years, with a median of $14.7 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Interest Expenses surged 266.67% in 2023, then tumbled 57.87% in 2024.
• A 5-year view of Interest Expenses shows it stood at $12.8 million in 2022, then jumped by 69.53% to $21.7 million in 2023, then slumped by 31.8% to $14.8 million in 2024, then decreased by 0.68% to $14.7 million in 2025, then fell by 25.17% to $11.0 million in 2026.
• The last three Interest Expenses figures came in at $11.0 million (Q1 2026), $14.7 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.